Anti-Dectin-2 CLEC6A Antibody (Monoclonal, ABM2H28)

Product Name

Anti-Dectin-2 CLEC6A Antibody (Monoclonal, ABM2H28)

View all CLEC6A Antibodies

SKU/Catalog Number

M11863

Size

100 µg

Form

Liquid

Description

Boster Bio Anti-Dectin-2 CLEC6A Antibody (Monoclonal, ABM2H28) (Catalog# M11863). Tested in IHC, FACS, WB application(s). This antibody reacts with Mouse, Human.

Storage & Handling

Store the antibody at 4°C, stable for 6 months. For long-term storage, store at -20°C. Avoid repeated freeze and thaw cycles.

Cite This Product

Anti-Dectin-2 CLEC6A Antibody (Monoclonal, ABM2H28) (Boster Biological Technology, Pleasanton CA, USA, Catalog # M11863)

Host

Mouse

Contents

100 µg in 200 µl PBS containing 0.05% stabilizing protein and 0.05% sodium azide
This antibody is supplied in a stabilized formulation.
Compatibility with conjugation reactions depends on the chemistry of the conjugation method used.
For conjugation methods that are not compatible with the stabilizing components present in this formulation, a carrier-free antibody format is required.

Clonality

Monoclonal

Clone Number

ABM2H28

Isotype

IgG2a Kappa

Immunogen

A partial length recombinant Dectin-2 protein (amino acids 70-230)

Cross-reactivity

Does not cross-react with primate, avian or amphibian GR.

Reactive Species

M11863 is reactive to CLEC6A in Human, Mouse

Observed Molecular Weight

68 kDa

Calculated molecular weight

24.0 kDa

Background of CLEC6A

The regions of relatively constant sequence beyond the variable regions of immunoglobulins are termed constant regions (C regions) and are present in both the heavy and light chains. With very few exceptions, the sites of attachment for carbohydrates on immunoglobulins are located in these C regions. These regions also function to hold the variable regions together by using the disulfide bond between them. The C regions facilitate interaction with the antigen by increasing the maximum rotation of the immunoglobulin arms. Reportedly, a large population of patients with recurrent respiratory tract infection has low IgG4 concentrations. IgG4-related sclerosing disease has been recognized as a systemic disease entity characterized by an elevated serum IgG4 level, sclerosing fibrosis, and diffuse lymphoplasmacytic infiltration with the presence of many IgG4-positive plasma cells.IgG4 is overexpressed in inflammatory pseudotumor (IPT) and under expressed in inflammatory myofibroblastic tumor (IMT). In pulmonary nodular lymphoid hyperplasia (PNLH), there are an increased number of IgG4+ plasma cells.

Antibody Validation

Boster validates all antibodies on WB, IHC, ICC, Immunofluorescence, and ELISA with known positive control and negative samples to ensure specificity and high affinity, including thorough antibody incubations.

View more details

Applications

M11863 is guaranteed for IHC, WB, FACS Boster Guarantee

Recommend Dilution

Western blot: 2-4 µg/ml
FACS analysis: 0.5 µg/10^6 cells
IHC: 5 µg/ml

Validation Images & Assay Conditions

See full target information CLEC6A

Here are featured tools and databases that you might find useful.

• Boster's Pathways Library
• Protein Databases
• Bioscience Research Protocol Resources
• Data Processing & Analysis Software
• Photo Editing Software
• Scientific Literature Resources
• Research Paper Management Tools
• Molecular Biology Software
• Primer Design Tools
• Bioinformatics Tools
• Phylogenetic Tree Analysis